Quest Diagnostics Lifts FY View on Higher 2Q Sales, Profit

Dow Jones

Jul 23

Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter.

The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the quarter ended June 30, compared with $282 million, or $2.47 a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were $3.12, ahead of the $2.82 anticipated by analysts, according to FactSet.

Revenue rose 10% to $3.04 billion. Analysts surveyed by FactSet had forecast revenue of $2.97 billion.

The sales performance was driven by organic growth across Quest's physician, hospital and consumer businesses, Chief Executive Jim Davis said.

Quest now projects full-year revenue to be $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.90 billion.

Adjusted earnings per share are expected to be $11.05 to $11.25, compared with the previous outlook of $10.63 to $10.83.

Analysts are projecting $11.85 billion in sales and $10.75 a share in adjusted earnings, according to FactSet.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

July 23, 2026 06:59 ET (10:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653741277"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653741277\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653741277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653741277","market":"fut","top_or_hot":-1,"title":"Quest Diagnostics Lifts FY View on Higher 2Q Sales, Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. \n</p>\n<p>\n  The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the quarter ended June 30, compared with $282 million, or $2.47 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were $3.12, ahead of the $2.82 anticipated by analysts, according to FactSet. \n</p>\n<p>\n  Revenue rose 10% to $3.04 billion. Analysts surveyed by FactSet had forecast revenue of $2.97 billion. \n</p>\n<p>\n  The sales performance was driven by organic growth across Quest's physician, hospital and consumer businesses, Chief Executive Jim Davis said. \n</p>\n<p>\n  Quest now projects full-year revenue to be $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.90 billion. \n</p>\n<p>\n  Adjusted earnings per share are expected to be $11.05 to $11.25, compared with the previous outlook of $10.63 to $10.83. \n</p>\n<p>\n  Analysts are projecting $11.85 billion in sales and $10.75 a share in adjusted earnings, according to FactSet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 06:59 ET (10:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Lifts FY View on Higher 2Q Sales, Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Lifts FY View on Higher 2Q Sales, Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-23 18:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. \n</p>\n<p>\n  The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the quarter ended June 30, compared with $282 million, or $2.47 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, adjusted per-share earnings were $3.12, ahead of the $2.82 anticipated by analysts, according to FactSet. \n</p>\n<p>\n  Revenue rose 10% to $3.04 billion. Analysts surveyed by FactSet had forecast revenue of $2.97 billion. \n</p>\n<p>\n  The sales performance was driven by organic growth across Quest's physician, hospital and consumer businesses, Chief Executive Jim Davis said. \n</p>\n<p>\n  Quest now projects full-year revenue to be $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.90 billion. \n</p>\n<p>\n  Adjusted earnings per share are expected to be $11.05 to $11.25, compared with the previous outlook of $10.63 to $10.83. \n</p>\n<p>\n  Analysts are projecting $11.85 billion in sales and $10.75 a share in adjusted earnings, according to FactSet. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 06:59 ET (10:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DGX","symbol_name":"奎斯特诊疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653741277","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653741277","pubTimestamp":1784804340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter.The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the quarter ended June 30, compared with $282 million, or $2.47 a share, a year earlier.Stripping out certain one-time items, adjusted per-share earnings were $3.12, ahead of the $2.82 anticipated by analysts, according to FactSet.Revenue rose 10% to $3.04 billion. Analysts surveyed by FactSet had forecast revenue of $2.97 billion.The sales performance was driven by organic growth across Quest's physician, hospital and consumer businesses, Chief Executive Jim Davis said.Quest now projects full-year revenue to be $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.90 billion.Adjusted earnings per share are expected to be $11.05 to $11.25, compared with the previous outlook of $10.63 to $10.83.Analysts are projecting $11.85 billion in sales and $10.75 a share in adj","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DGX":"奎斯特诊疗"},"translate_title":"Quest Diagnostics 因第二季度销售额和利润增加而提升财年前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1.5},"content_text":"Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. \n\n\n  The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the quarter ended June 30, compared with $282 million, or $2.47 a share, a year earlier. \n\n\n  Stripping out certain one-time items, adjusted per-share earnings were $3.12, ahead of the $2.82 anticipated by analysts, according to FactSet. \n\n\n  Revenue rose 10% to $3.04 billion. Analysts surveyed by FactSet had forecast revenue of $2.97 billion. \n\n\n  The sales performance was driven by organic growth across Quest's physician, hospital and consumer businesses, Chief Executive Jim Davis said. \n\n\n  Quest now projects full-year revenue to be $11.95 billion to $12.05 billion, up from a previous range of $11.78 billion to $11.90 billion. \n\n\n  Adjusted earnings per share are expected to be $11.05 to $11.25, compared with the previous outlook of $10.63 to $10.83. \n\n\n  Analysts are projecting $11.85 billion in sales and $10.75 a share in adjusted earnings, according to FactSet. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 06:59 ET (10:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}